IASO-Innovent Tout Favourable Profile Of BCMA CAR-T

 
• By Dexter Jie Yan

J&J partner Nanjing Legend and UniCAR developer CARsgen also race for the first China approval for BCMA targeting CAR-T therapy.

IASO ASH updates
IASO updates BCMA CAR-T’s first efficacy data for CAR-T failed MM patients • Source: Alamy

More from China

More from Focus On Asia